PICATO
PeakNDATOPICALGEL
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
3/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PICATO is a topical gel formulation approved in 2012 for dermatological use, currently in peak commercial lifecycle. The drug's mechanism of action and specific indications are not publicly detailed in available data, but the topical gel modality suggests localized skin treatment. As a small-molecule topical agent, it targets patients requiring non-systemic dermatological intervention.
Peak6.6 years to LOE
Peak-stage topical indicates mature, stable market position with established commercial infrastructure; team size likely optimized for maintenance and line extension.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients
Started Dec 2017
0Molluscum Contagiosum
The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice
Started Dec 2015
440 enrolled
Actinic Keratosis
Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin
Started Nov 2015
23 enrolled
Actinic KeratosisPhoto-aged Skin
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
Started Feb 2015
40 enrolled
Anogenital Warts
Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis
Started Jan 2015
20 enrolled
Actinic Keratosis
Worked on PICATO at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.